Summary
Gestational trophoblastic disease (GTD) forms a group of disorders spanning the conditions of complete and partial molar pregnancies through to the malignant conditions of invasive mole, choriocarcinoma and the very rare placental site trophoblastic tumour (PSTT). There are reports of neoplastic transformation of atypical placental site nodules to placental site trophoblastic tumour.
If there is any evidence of persistence of GTD, most commonly defined as a persistent elevation of beta human chorionic gonadotrophin (βhCG), the condition is referred to as gestational trophoblastic neoplasia (GTN).
The purpose of this guideline is to describe the presentation, management, treatment and follow-up of GTD and GTN. It also provides advice on future pregnancy outcomes and the use of contraception.
Version history
The first edition of this guideline was published in 1999 (as The Management of Gestational Trophoblastic Disease); the second edition was published in 2004 (as The Management of Gestational Trophoblastic Neoplasia); the third edition was published in 2010 (as The Management of Gestational Trophoblastic Disease). This is the fourth edition of this guideline, published in 2020; reviewed in 2023 – no update required. Next review date: 2026.
Developer declaration of interests
Professor J Tidy: None declared.
Professor M Seckl: None declared.
Professor BW Hancock: None declared.